The decision made with regard to these NICE 30 day TAs can now be found at: https://ntag.nhs.uk/meetings/decision-summaries/
- TA918 – Bimekizumab for treating axial spondyloarthritis
- TA920 – Tofacitinib for treating active ankylosing spondylitis
- TA925 – Mirikizumab for treating moderately to severely active ulcerative colitis
- TA927 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments